Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARVN
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
ARVN
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

ARVN Similar Chart Price Prediction

The price of ARVN is predicted to go up 25.59%, based on the high correlation periods with CTHR. The similarity of these two price pattern on the periods is 94.49%.

stocks logo

ARVN

stocks logo

CTHR

Up: 25.59%Similarity: 94.49%

ARVN Revenue Forecast

ARVN EPS Forecast

ARVN FAQs

What is bull’s view on ARVN?

ARVN stock is viewed positively by bulls due to its promising clinical pipeline, particularly the phase 3 trial of vepdegestrant for metastatic breast cancer, which could significantly outperform standard treatments. Analysts like Bank of America and HC Wainwright have set high price targets of $57 and $87, respectively, compared to the current price of $18.76, reflecting strong upside potential. Additionally, its robust cash position of $1.1 billion and strategic partnership with Pfizer further bolster confidence in its growth prospects.

What is bear's view on ARVN?

ARVN stock is currently trading at $18.62, significantly below its 6-month high of $26.25, reflecting a 29% decline. Bears argue that despite promising clinical developments, the stock faces high execution risks, particularly with its lead candidate vepdegestrant in phase 3 trials, and the broader biotech sector's volatility. Additionally, the company's cash burn rate and reliance on trial success make it vulnerable to further downside.

What is ARVN revenue forecast for next quarter？

The market consensus for ARVN's revenue in the upcoming quarter is projected to be approximately $37.454M USD.

What is ARVN eps forecast for next quarter？

The market consensus for ARVN's eps in the upcoming quarter is projected to be approximately $1.24 USD.

ARVN VS S&P500

Ask Intellectia about ARVN

ARVN Analyst's Forecast

Sudan Loganathan

Stephens & Co.

Buy

Price Target

$55

Upside

+138.2%

Stephens initiated coverage of Arvinas (ARVN) with an Overweight rating and $55 price target. The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or TPD, technology and commercial and clinical-stage rare disease-focused companies. Arvinas is a "leader in this TPD therapeutic technology" that is expected to have the first TPD approved for the market in the next 18-24 months, the analyst noted. Its lead asset is in combination with Pfizer's (PFE) IBRANCE for advanced breast cancer and its pipeline is testing the first TPDs in neurologic disorders, the analyst added.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free